208 related articles for article (PubMed ID: 37776237)
21. Cuproptosis-related lncRNAs ovarian cancer: Multi-omics analysis of molecular mechanisms and potential therapeutic targets.
Wang Y; Liang Q; Xu L; Xiong J; Gao K; Xu P; Huang W
Environ Toxicol; 2024 Mar; 39(3):1650-1665. PubMed ID: 38019212
[TBL] [Abstract][Full Text] [Related]
22. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
23. A signature based on glycosyltransferase genes provides a promising tool for the prediction of prognosis and immunotherapy responsiveness in ovarian cancer.
Xu X; Wu Y; Jia G; Zhu Q; Li D; Xie K
J Ovarian Res; 2023 Jan; 16(1):5. PubMed ID: 36611197
[TBL] [Abstract][Full Text] [Related]
24. A cuproptosis-related genes signature associated with prognosis and immune cell infiltration in osteosarcoma.
Yang W; Wu H; Tong L; Wang Y; Guo Q; Xu L; Yan H; Yin C; Sun Z
Front Oncol; 2022; 12():1015094. PubMed ID: 36276092
[TBL] [Abstract][Full Text] [Related]
25. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
Front Immunol; 2022; 13():919231. PubMed ID: 35967366
[TBL] [Abstract][Full Text] [Related]
26. Novel Molecular Subtyping Scheme Based on In Silico Analysis of Cuproptosis Regulator Gene Patterns Optimizes Survival Prediction and Treatment of Hepatocellular Carcinoma.
Jiang H; Chen H; Wang Y; Qian Y
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762710
[TBL] [Abstract][Full Text] [Related]
27. Arecoline Is Associated With Inhibition of Cuproptosis and Proliferation of Cancer-Associated Fibroblasts in Oral Squamous Cell Carcinoma: A Potential Mechanism for Tumor Metastasis.
Li J; Chen S; Liao Y; Wang H; Zhou D; Zhang B
Front Oncol; 2022; 12():925743. PubMed ID: 35875097
[TBL] [Abstract][Full Text] [Related]
28. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma.
Li J; Yin J; Li W; Wang H; Ni B
Cancer Cell Int; 2023 Jan; 23(1):7. PubMed ID: 36647100
[TBL] [Abstract][Full Text] [Related]
29. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.
Yang J; Liu K; Yang L; Ji J; Qin J; Deng H; Wang Z
Front Immunol; 2023; 14():1174762. PubMed ID: 37287976
[TBL] [Abstract][Full Text] [Related]
30. Development and Verification of a novel cuproptosis- and immune-associated based prognostic genetic signature for pancreatic ductal adenocarcinoma.
Xu X; Liang JH; Xu QC; Yin XY
Clin Res Hepatol Gastroenterol; 2023 Mar; 47(3):102089. PubMed ID: 36707046
[TBL] [Abstract][Full Text] [Related]
31. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma.
Li Y; Zeng X
Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728
[No Abstract] [Full Text] [Related]
32. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
Pan Y; Zhang Q; Zhang H; Kong F
Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
[TBL] [Abstract][Full Text] [Related]
33. Identification of cuproptosis and ferroptosis-related subgroups and development of a signature for predicting prognosis and tumor microenvironment landscape in hepatocellular carcinoma.
Yang BF; Ma Q; Hui Y; Gao XC; Ma DY; Li JX; Pei ZX; Huang BR
Transl Cancer Res; 2023 Dec; 12(12):3327-3345. PubMed ID: 38192999
[TBL] [Abstract][Full Text] [Related]
34. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
35. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
Wang S; Bai H; Fei S; Miao B
Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
[TBL] [Abstract][Full Text] [Related]
36. Development of a novel prognostic signature based on single-cell combined bulk RNA analysis in breast cancer.
Xiao Y; Hu G; Xie N; Yin L; Pan Y; Liu C; Lou S; Zhu C
J Gene Med; 2024 Feb; 26(2):e3673. PubMed ID: 38404059
[TBL] [Abstract][Full Text] [Related]
37. Identification of novel molecular subtypes and a signature to predict prognosis and therapeutic response based on cuproptosis-related genes in prostate cancer.
Zhang J; Jiang S; Gu D; Zhang W; Shen X; Qu M; Yang C; Wang Y; Gao X
Front Oncol; 2023; 13():1162653. PubMed ID: 37205181
[TBL] [Abstract][Full Text] [Related]
38. Construction and validation of a bladder cancer risk model based on autophagy-related genes.
Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H
Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018
[TBL] [Abstract][Full Text] [Related]
39. EREG is the core onco-immunological biomarker of cuproptosis and mediates the cross-talk between VEGF and CD99 signaling in glioblastoma.
Zhou Y; Xiao D; Jiang X; Nie C
J Transl Med; 2023 Jan; 21(1):28. PubMed ID: 36647156
[TBL] [Abstract][Full Text] [Related]
40. Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq.
Zhang D; Lu W; Cui S; Mei H; Wu X; Zhuo Z
J Ovarian Res; 2022 Nov; 15(1):123. PubMed ID: 36424614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
